Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting

Phua, Chee Ee; Bustam, Anita Zarina; Yusof, Mastura Md; Saad, Marniza; Yip, Cheng‐Har; Taib, Nur Aishah Mohd; Ng, Char Hong; Teh, Yew Ching

doi:10.7314/apjcp.2012.13.9.4623

Cited by 8 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy, radiotherapy and mastectomy have long been used in breast cancer treatments (Wijayahadi et al 2007). Although effective, these therapies nevertheless cause adverse side effects such as ovarian failure (tiong et al 2014) and neutropenia (Phua et al 2012) strategy for breast cancer treatment. Immunotherapy stimulates specific anticancer immune cells that destroy and inhibit cancer cell growth without affecting the normal cells (Pflanz et al 2002).…”

Section: Discussionmentioning

confidence: 99%

Cytotoxicity, Regulation of Apoptotic and Anti-apoptotic Gene Expression by IL-27 in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines

Yap¹,

Nadarajah²,

Shidik³

et al. 2018

JSKM

View full text Add to dashboard Cite

Breast cancer is one of the commonest cancers among women. Conventional therapies cause adverse side effects in patients. Cytokine immunotherapy such as has been sought as an alternative cancer treatment in recent years. has been shown to improve anticancer immunity and anti-angiogenesis in cancers, however, its effect on apoptotic and anti-apoptotic gene expression especially in breast cancers is yet to be explored. Cytotoxicity of and cancerous breast cell lines was first determined for 24-72 h in this study. The results indicated that IL-27 treatment did not retard 184b5 cell growth, however, did inhibit and respectively. Apoptotic (TRAIL, FADD, FAS, and anti-apoptotic (BCL-2, AKT, and COX-2) genes were then amplified from untreated (control) and treated breast cancer cells and studied. TRAIL, caspase-3, caspase-8 gene expression was significantly (p < 0.05) upregulated in treated MCF-7 (442 ng/ml) and MDA-MB-231 (457 ng/ml) cells. Expression of FADD and FAS genes was not detected in both control and treated MCF-7 and MDA-MB-231 cells. COX-2 gene was also not expressed by MCF-7 cells, but reduced significantly (p < 0.05) in treated MDA-MB-231 cells. In MDA-MB-231 cells, IL-27 treatment seemed to slightly enhance the expression of AKT and BCL-2 genes which, on the other hand, was downregulated in treated MCF-7 cells. Conclusively, IL-27 is able to inhibit breast cancer cell growth and regulate apoptotic and anti-apoptotic gene expression in breast cancer cells. Keywords: IL-27; cytokine immunotherapy; triple negative breast cancer; invasive ductal breast cancerABStRAK Kanser payu dara adalah antara kanser yang paling biasa dihidapi oleh wanita. Rawatan konvensional menyebabkan kesan sampingan teruk dalam pesakit. Imunoterapi sitokin seperti interleukin-27 (IL-27) telah digunakan sebagai rawatan alternatif sejak kebelakangan ini. IL-27 telah terbukti dapat menambah baik imuniti antikanser dan aktiviti anti-angiogenesis dalam kanser, namun kesannya pada pengekspresan gen apoptotik and anti-apoptotik terutamanya pada kanser payu dara masih belum diterokai. Dalam kajian ini, kesan sitotoksisiti IL-27 pada sel selanjar bukan kanser (184b5) dan kanser (MCF-7 dan MDA-MB-231) ditentukan pada 24-72 jam dalam kajian ini. Dapatan kajian menunjukkan rawatan IL-27 tidak menjejaskan pertumbuhan sel 184b5, namun menghalang pertumbuhan sel and FADD, FAS, caspase-3 dan caspase-8) and anti-apoptotik (BCL-2, AKT, dan COX-2) kemudiannya diamplifikasikan daripada sel kanser payu dara kawalan dan terawat serta dikaji. Pengekspresan gen TRAIL, caspase-3 dan caspase-8 telah meningkat secara signifikan (p < 0.05) dalam sel yang dirawat. Pengekspresan gen FADD dan FAS gagal dikesan dalam sel MCF-7 dan MDA-MB-231, mahupun sel kawalan atau terawat. Gen COX-2 tidak diekspreskan oleh sel MCF-7 tetapi pengekspresannya telah menurun secara signifikan (p < 0.05) dalam sel MDA-MB-231 yang dirawat. Dalam sel MDA-MB-231, rawatan IL-27 meningkatkan pengekspresan gen AKT dan BCL-2, namun pengekspresan kedua-dua gen tersebut telah menurun...

show abstract

Section: Discussionmentioning

confidence: 99%

Cytotoxicity, Regulation of Apoptotic and Anti-apoptotic Gene Expression by IL-27 in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines

Yap¹,

Nadarajah²,

Shidik³

et al. 2018

JSKM

View full text Add to dashboard Cite

show abstract

“…Subsequently, taxanes have been used either alone or with anthracyclines and have shown improved pCR rates, with single agent docetaxel achieving pCR in 16-20% patients (Von Minckwitz et al, 2008). However, mortality and febrile neutropenia ar relatively common (Phua et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer : Institutional Experience

Gogia

Raina²,

Deo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to assess the response rates (clinical and pathological ) with docetaxel and epirubicin combination chemotherapy and its effect on outcome. Materials and Methods: We retrospectively analysed locally advanced breast cancer (LABC) patients who received NACT from January 2008 to December 2012 in our tertiary care centre. LABC constituted 37% of all breast cancer cases and 120 patients fulfilled the eligibility criteria. The regimens used for NACT were, six cycles of DEC (docetaxel 75 mg/m 2 , epirubicin 75 mg/ m 2 , cyclophosphamide 500 mg/m 2 on Day 1, 3 weekly) and a sequential regimen (4 cycles of FEC, 5-flurouracil 600 mg/m², epirubicin 75 mg/m², cyclophosphamide 600 mg/m² followed by 4 cycles of docetaxel 85 mg/m 2 ). Results: The median age was 47 years (range 23-72). Ninety six ( 80 %) had T4 disease and 90% had clinically palpable lymph nodes at diagnosis. The median size of primary tumor at presentation was 5.9 cm. Hormone receptor positivity was seen in 55% and HER2/neu positivity, in 25%. Triple negative breast cancers constituted 25 % of the cases. The overall clinical response rate ( complete or partial ) was 85% and pathological complete responses were obtained in 15%. Four cases defaulted, 5 patients died of treatment related toxicity and 15% developed febrile neutropenia on DEC. The median duration of follow up was 22 months. The median time to relapse was 20 months and the 3 year relapse free and overall survival rates were 50% and 70% respectively. Conclusions: LABC constituted 37% of all breast cancer cases at our institute. With NACT, pCR was seen in 15% of the cases. Sequential chemotherapy was better tolerated than concurrent anthracyline and taxane chemotherapy with a similar pCR.

show abstract

Prevalence of Febrile Neutropenia in Breast Cancer Patients Received Adjuvant Paclitaxel Treatment

Areepium

2014

Value in Health

View full text Add to dashboard Cite

A 7 1 9 -A 8 1 3 A733 pared to well-moderately differentiated tumor (p = 0.0172). Having poorly differentiated tumor was related to higher death rate immediately after diagnosis, but this disadvantageous effect gradually vanished over time. Fourteen comorbidity conditions were significantly associated with shorter time-to-death. ConClusions: Effective control of comorbidity in PCa patients should help improve life expectancy and lead to prolonged survival. Further research is needed to understand mechanisms in which individual and contextual factors impact PCa survival.objeCtives: Bevacizumab is a humanized monoclonal antibody that produces angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). Bevacizumab was approved for combination use with standard chemotherapy for metastatic colon cancer. This research aims to conduct a systematic review on meta-analysis and cost-effectiveness analysis on standard chemotherapy plus bevacizumab for patients with metastatic colorectal cancer (mCRC) to explore the efficacy, safety and cost-effectiveness on the addition of bevacizumab. Methods: A systematic literature search on both meta-analysis and cost-effectiveness analysis of chemotherapy plus bevacizumab on databases was carried out in several databases, such as MEDLINE, PubMed, CNKI chemotherapy. Articles were included based on specific inclusion and exclusion criteria. Results: Six included analyses indicate that chemotherapy plus bevacizumab significantly prolonged progressionfree survival (PFS) and overall survival (OS). The risk of hypertension, bleeding and proteinuria are significantly increased, whereas there are no significant differences on gastric perforation, thrombosis. Eleven cost-effectiveness analysis demonstrate that the addition of bevacizumab lead to higher medical cost and health care cost. In most countries involved in this review, chemotherapy plus bevacizumab is not cost-effective comparing with standard chemotherapy. However, the medical and health care cost of using bevacizumab is lower than cetuximab. ConClusions: The addition of bevacizumab significantly increases survival benefits and slightly leads to more adverse events. Due to higher cost of bevacizumab, it is not costeffective therapy for mCRC patients. According to the potential considerable differences on economic status, epidemiology, clinical effectiveness, the generalizability of included meta-analyses and cost-effectiveness analyses need to be taken into account. Analyses based on China local data should be processed in the future.

show abstract

Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting

Cited by 8 publications

References 26 publications

Cytotoxicity, Regulation of Apoptotic and Anti-apoptotic Gene Expression by IL-27 in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines

Cytotoxicity, Regulation of Apoptotic and Anti-apoptotic Gene Expression by IL-27 in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines

Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer : Institutional Experience

Prevalence of Febrile Neutropenia in Breast Cancer Patients Received Adjuvant Paclitaxel Treatment

Contact Info

Product

Resources

About